TY - JOUR
T1 - Meta-analysis of the effect of thiazolidinediones on serum C-reactive protein levels
AU - Qayyum, Rehan
AU - Adomaityte, Jurga
PY - 2006/3/1
Y1 - 2006/3/1
N2 - We conducted a meta-analysis of randomized clinical trials to evaluate the effect of thiazolidinediones on serum C-reactive protein levels. Compared with placebo, treatment with thiazolidinediones significantly decreased the serum C-reactive protein levels (mean -0.82 mg/L, 95% confidence interval -1.15 to -0.49 mg/L, p <0.0001). In a subgroup analysis, the effect of thiazolidinediones on the serum C-reactive protein levels was more pronounced in diabetic patients (mean -1.24 mg/L, 95% confidence interval -2.15 to -0.32 mg/L, p = 0.008) compared with nondiabetic patients (mean -0.27 mg/L, 95% confidence interval -0.41 to -0.14 mg/L, p <0.0001).
AB - We conducted a meta-analysis of randomized clinical trials to evaluate the effect of thiazolidinediones on serum C-reactive protein levels. Compared with placebo, treatment with thiazolidinediones significantly decreased the serum C-reactive protein levels (mean -0.82 mg/L, 95% confidence interval -1.15 to -0.49 mg/L, p <0.0001). In a subgroup analysis, the effect of thiazolidinediones on the serum C-reactive protein levels was more pronounced in diabetic patients (mean -1.24 mg/L, 95% confidence interval -2.15 to -0.32 mg/L, p = 0.008) compared with nondiabetic patients (mean -0.27 mg/L, 95% confidence interval -0.41 to -0.14 mg/L, p <0.0001).
UR - http://www.scopus.com/inward/record.url?scp=32844471882&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=32844471882&partnerID=8YFLogxK
U2 - 10.1016/j.amjcard.2005.09.105
DO - 10.1016/j.amjcard.2005.09.105
M3 - Article
C2 - 16490432
AN - SCOPUS:32844471882
SN - 0002-9149
VL - 97
SP - 655
EP - 658
JO - American Journal of Cardiology
JF - American Journal of Cardiology
IS - 5
ER -